Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Director | August 03, 2026 | August 05, 2026 |
| Caris Life Sciences, Inc.CAI · Entity 3706 | Director | August 14, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,689 |
Ending reported balance
After 2026-08-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-03 · Sale · Disposed 593 · Balance 3,282 Row 2 · 2026-08-04 · Sale · Disposed 593 · Balance 2,689 |
Caris Life Sciences, Inc.
Report date August 14, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,813 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 13,192 · Balance 31,813 F1: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 14, 2026 21:42 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | GrantCommon Stock | 13,192 | $0.00 | $0.00 |
DisclosureSEC source: 0002038687-26-000007 · wk-form4_1786743756.xml · nonDerivative · entry 1 Minor Lloyd · CIK 0002038687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,813 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| August 04, 2026 Filed Aug 5, 2026 20:03 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 593 | $200.96 | $119,169.28 |
DisclosureSEC source: 0000875045-26-000076 · form4.xml · nonDerivative · entry 2 Minor Lloyd · CIK 0002038687 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,689 Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:03 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 593 | $203.34 | $120,580.62 |
DisclosureSEC source: 0000875045-26-000076 · form4.xml · nonDerivative · entry 1 Minor Lloyd · CIK 0002038687 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,282 Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,505 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000054 · form4.xml · nonDerivative · entry 1 Minor Lloyd · CIK 0002038687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,875 F1 · shares: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 12:48 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | GrantCommon Stock | 2,492 | $20.06 | $49,989.52 |
DisclosureSEC source: 0002038687-26-000004 · wk-form4_1772455734.xml · nonDerivative · entry 1 Minor Lloyd · CIK 0002038687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,621 F1 · kind: Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:54 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 2,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-017766 · form4.xml · nonDerivative · entry 1 Minor Lloyd · CIK 0002038687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,370 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.